Search alternatives:
significant groups » significant group (Expand Search), significant gradual (Expand Search), significant amount (Expand Search)
mean decrease » a decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
significant groups » significant group (Expand Search), significant gradual (Expand Search), significant amount (Expand Search)
mean decrease » a decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
61
Absorption peaks of groups.
Published 2025“…Finally, considering all monomer surfactants’ abilities to reduce surface tension, decrease contact angles and promote dust settling in solutions, we selected five surfactants (AES, MES-30, AEO-9, CDEA and CHSB) for blending based on their excellent performance in tests. …”
-
62
-
63
-
64
-
65
-
66
KEGG enrichment pathway based on the significant metabolites detected in RSA and control group.
Published 2023“…<p>KEGG enrichment pathway based on the significant metabolites detected in RSA and control group.…”
-
67
Significant GO terms enriched based on the DEGs in control vs. noise groups.
Published 2024“…<p>Significant GO terms enriched based on the DEGs in control vs. noise groups.…”
-
68
Significant GO terms enriched based on the DEGs in control vs. noise groups.
Published 2024“…<p>Significant GO terms enriched based on the DEGs in control vs. noise groups.…”
-
69
Significant KEGG pathways enriched based on the DEGs in control vs. noise groups.
Published 2024“…<p>Significant KEGG pathways enriched based on the DEGs in control vs. noise groups.…”
-
70
Plot of mean simulated power with 95 percentile (2.5 & 97.5%) for select DNAm differences.
Published 2024Subjects: -
71
Variability and correlations decrease during task states in human fMRI data.
Published 2020“…<b>h)</b> We found that the average correlation for each brain region, decreased for each brain region during task state. …”
-
72
-
73
-
74
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
75
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
76
-
77
-
78
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
79
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
80
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: